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ABSTRACT
Multiple Myeloma (MM) is a treatable, yet incurable, malignancy of bone marrow
plasma cells. This cancer affects many patients and many succumb to relapse of tumor burden
despite a large number of available chemotherapeutic agents developed for therapy. This is
because MM tumors are heterogeneous and receive protection from therapeutic agents by the
microenvironment and other mechanisms including homologous MM-MM aggregation.
Therefore, therapy failure and frequent patient relapse is due to the evolution of drug resistance,
not a lack of available drugs. To analyze and understand this problem, the evolution of drug
resistance has been explored and presented herein. We seek to describe the methods through
which MM cells become resistant to therapy, and how this resistance evolves throughout a
patient’s treatment history. We achieve this in five steps.
First we review the patient’s clinical history, including treatments and changes in
tumor burden. Second, we trace the evolutionary tree of sub-clones within the tumor
burden using standard of care fluorescence in situ hybridization (FISH). Thirdly,
immunohistochemistry slides are stained and aligned to quantify the level of environmental
protection received by surrounding cells and plasma in the bone marrow microenvironment
(coined environment mediated drug resistance score [EMDR]). The fourth analysis type is
produced through a novel 384-well plate ex vivo chemosensitivity assay to quantify sensitivity of
primary MM cells to chemotherapeutic agents and extrapolate these findings to 90-day clinical
response predictions. In addition to direct clinical application in the choice of best treatment, this
tool was also used to study changes in sensitivity of patient tumors to other drugs, and it was
iii

observed that, upon relapse, in addition to developing resistance to the current line of therapy,
tumors become cross-resistant to agents that they were never exposed to. Finally, MM-MM
homologous aggregation is quantified to assess the level of drug resistance contributed by
clustering of patient tumor cells, which causes upregulation of Bcl-2 expression and other
resistance mechanisms1.
The findings of such experimentation improve comprehension of the driving factors that
contribute to drug resistance evolution on a personalized treatment basis. The aforementioned
factors all contribute in varying degrees for unique patient cases, seven of which are presented in
depth for this project. In summary: Environmental protection plays a critical initial role in drug
resistance, which is followed by increase in tumor genetic heterogeneity as a result of mutations
and drug-induced Darwinian selection. Eventually, environment-independent drug resistant subpopulations emerge, allowing the tumor to spread to unexplored areas of the bone marrow while
maintaining inherited drug resistant phenotype2. It is our hope that these findings will help in
shifting perspective regarding optimal management of MM by finding new therapeutic
procedures that address all aspects of drug resistance to minimize chance of relapse and improve
quality of life for patients.
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CHAPTER 1: INTRODUCTION
Multiple Myeloma (MM) is an incurable cancer of the bone marrow. Despite many
available treatment options, prognosis remains quite poor and relapse occurs in many patients3.
This relapse is known to occur due to genetic mutations that can lead to high risk tumor
subpopulations4,5, changes in the tumor microenvironment6,7, and changes in phenotypic
interaction by MM-MM cell adhesion/interaction8. High-risk patients have a low median overall
survival (<2 years) despite the approval of many new drugs. This suggests that the problem is not
lack of drugs but our lack of knowledge of how tumors evade therapy and develop drug
resistance. Our goal, therefore, is to delay the rate of evolution of drug resistance and increase
patient survival by one order of magnitude, reaching a functional cure. We seek here to further
quantify the mechanisms of drug resistance and assess how they evolve throughout the course of
therapy. This project aims to quantify the evolution of drug resistance across sequential biopsies
of seven patients with respect to genetic abnormality, ex vivo response prediction, EMDR, and
homologous MM-MM adhesion. First, we seek to understand the genetic abnormalities that drive
drug resistance evolution.
Complex and multiple chromosomal abnormalities present themselves in the plasma cells
of MM4,5,9. MM karyotypes can be analyzed for these abnormalities by means of interphase
fluorescence in situ hybridization (FISH), which can analyze the chromosomes of non-dividing
cells5,9-11. FISH probes are utilized in pairs and primarily apply to studies of monosomies/
trisomies, changes in chromosomes 17 and 13, and translocations of the immunoglobulin heavychain locus. This is due to the high clinical risk of poor prognosis typically associated with these
1

abnormalities, including the translocations of 14q32 (IGH) and 11q13 (CCND1) which causes
overexpression of CCND1 and cell cycle dysregulation, and IGH translocation with 4p16
(FGFR3) which causes overexpression of MMSET leading to apoptosis prevention3,12-18. There is
an additional risk associated with a deletion of chromosome 13, which promotes clonal
expansion and is associated with hypodiploid MM, though there is no one specific genetic
consequence of alterations to this chromosome12.
FISH tests for these high-risk abnormalities, and thus not all genetic abnormalities are
portrayed in a FISH panel. In subsequent discussion of clonal dynamics, care must be taken to
define what is meant by a clone. The term clone, as it is presented here, refers to an identical
group of cells with respect to MM-FISH report results. It is unknown if these cells are truly
identical in areas other than genetic mutation detectable by the FISH probes. The chromosomal
abnormalities detected play a variety of roles in drug resistance through deregulation of crucial
proteins as discussed above. However, analysis of FISH alone as an indicator of drug resistance
in MM remains insufficient, as patients with the same genetic abnormalities commonly have
different clinical results19-21. We expect this is due to a multitude of additional factors including
therapeutic intervention, environment-mediated drug resistance (EMDR), and MM homologous
aggregation.
Another way to assess the changes in drug resistance throughout a patient’s treatment
history is to utilize the ex vivo results of experiments we performed using primary patient cells.
This 96-hour well plate experiment allows us to quantify the continuous viability of cells
obtained through bone marrow aspirates at Moffitt Cancer Center22. Through computational
techniques utilizing pharmacokinetic models published for therapeutic agents, extrapolation of
dose response can yield accurate predictions of clinical response for individual patients. These
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results may be used to analyze drug resistance upon relapse and shows strong patterns of crossresistance across the panel of chemotherapeutic agents. This data, though based on phenotype,
may be used in conjunction with genetic mutation information to glean further into the evolution
of drug resistance in MM. However, there are further methods that may be employed to continue
broadening the scope of analysis to this end.
Environment mediated drug resistance (EMDR) is a term used to describe the bone
marrow (BM) microenvironment’s promotion of cell survival to therapy, and consequent
contribution to minimal residual disease, through a variety of soluble and adhesive factors23-28.
One such physical factor, fibronectin (FN) is known to control survival and growth of MM
cells29. FN has been determined to play a prominent role in growth and drug resistance control in
MM due to the promoted secretion of the cytokine interleukin (IL)-624,29,30. FN adhesion to MM
cells causes activation of integrin heterodimers composed of integrins α4 or α5 and β1 through
intracellular signaling via protein tyrosine kinases (PTK) and receptor PTK31,32. Here, we
propose a metric to assess the level of EMDR in MM patients through co-localization of MM
membrane-bound β1 integrins and FN using immunohistochemistry (IHC) and digital image
analysis. This approach generates frequency distributions of the tumor burden and the degree of
EMDR protection to which they are submitted. If EMDR is a clinically relevant mechanism,
sequential biopsies should depict changes in these levels in accordance with increases in drug
resistance.
In addition to extracellular matrix- and stroma-derived factors, homologous (cell-cell)
adhesion also promotes drug resistance in hematologic tumors1,33. The formation of aggregates
among tumor cells (via 1.5% agarose solution in 96-well plates) has been shown to promote
resistance to drugs including Bortezomib and Doxorubicin through an increase in the level of
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Bcl-2, an anti-apoptotic protein1. Additionally, in solid tumors, the density of cell clusters poses
a barrier to drug penetration by affecting magnitude of diffusion gradients that improves drug
resistance with the formation of more compact, less invasive tumors33-36. Concurrently, the case
of decreased cell proliferation in multicellular spheroids of pancreatic cancer has been shown to
improve drug resistance through associated cascades in cell survival signaling, including cyclinCDK (cyclin-dependent kinases), which regulates progression through the cell cycle and allows
DNA injuries and chromosomal defects to be repaired37-39. The progression of tumor clustering
throughout patient treatment has also been observed in MM40. A known cause of MM clustering
is the expression of β-catenin that stimulates overexpressed signaling of Wnt, a paracrine growth
factor that can influence MM growth41,42. It has been determined that N-cadherin is consequently
over-expressed as the extracellular counterpart to β-catenin, and patient primary cells with high
expression of CDH2 (the gene that encodes N-cadherin) correlates with a high probability
(>83%) of high-risk genetic abnormalities such as t(4;14)(p16;q32) translocations and CCND1
(11q13) duplication, though the cause of the correlation between these two mechanisms of drug
resistance remains unknown43,44. These abnormalities suggest poor prognosis for MM patients,
and further strengthens the correlation between homologous adhesion of MM cells and drug
resistance. Analysis of primary MM cell clustering due to MM-MM adhesion can provide
additional insight into the evolution of drug resistance in patients.

4

CHAPTER 2: MATERIALS AND METHODS
2.1 Human Subjects/Clinical History
Redacted patient histories were obtained through the Total Cancer Care (TCC) Initiative
at Moffitt Cancer Center. Name, age, and gender were removed from provided data to comply
with anonymity of patients from researchers. However, blood test results showing tumor
progression through serum free light chain (SFLC) and M-spike levels, as well as biopsy dates
and therapeutic regimen utilized were all provided kindly by the Moffitt hospital.

2.2 Cell Lines and Primary Cell Protocols
Our previous work delves greatly into the procedures through which cell lines and
primary patient cells were obtained and utilized ex vivo45. H929 and MM1s MM cell lines were
cultured and utilized as positive control in ex vivo protocols. Primary cells from patients were
obtained through the TCC initiative and magnetic bead sorted to select for CD138+ primary MM
cells.

2.3 Ex vivo Procedures and Imaging
Additional work we have compiled and published in the Silva laboratory divulge great
detail in the seeding of cells ex vivo, the equipment utilized, and the software composed in house
to extrapolate experiment therapy response to clinical prediction46. Primary cells/cell lines are
seeded in a 384 well plate with collagen and patient stroma to replicate the bone marrow
microenvironment. Once incubated and spun to the same focal plane, drugs at relevant densities
5

(up to 31 plus control) were added to the plate and time-lapse imaging was run for 96 hours
(image acquisition every 30 minutes). These results were then extrapolated to determine
maximum tumor burden levels at 90-day clinical response for each patient utilizing
pharmacokinetics and parameterization of evolutionary models with ex vivo results.

2.4 FISH and Phylogenetic Analyses
FISH reports are provided in a revised format by the Moffitt Cancer Center. First, we
determine which probe results are abnormal from the Specific Probe Results report section, and
which ones are mutually exclusive of each other based on chromosomal location. Care must be
taken to realize that some abnormal results without translocation may simply be artifacts of a
different probe analysis since they are always done in pairs. From the principle of maximum
parsimony we expect that clonal dynamics of the tumor will follow the most ‘straight-line’ path
in terms of the phylogenetic tree. This also suggests a much more increased likelihood of
additional mutations presenting themselves stepwise through time, rather than the appearance
and disappearance of multiple abnormalities from subpopulations. We compare FISH reports
from sequential patient biopsies and create the tree based on these principles rather than
chronological emergence. The results are an understanding of the percentage of tumor burden
over time that contains the high-risk abnormalities tested in FISH and the phylogenetic tree of
these abnormal clone subpopulations. If these principles are not followed in clonal dynamic
determination, phylogenetic trees and subsequent results become overcomplicated and unclear. A
detailed diagram for proper FISH report analysis is presented in Figure 2.1.
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2.5 EMDR Score Determination and Calculation
EMDR score is based on bone marrow immunohistochemistry. Slides are requested and
provided by the Moffitt Tissue Core for integrin β1, FN, and CD138 with corresponding positive
and negative controls. All provided slides are scanned by the Moffitt Cancer Center Microscopy
Core at up to 20x magnification and cropped and aligned manually to the best of the user’s
ability in ImageJ. Our macro takes the slides and completes their alignment to overlay pixels of
each subsequent slide. The CD138 threshold value is determined based on the positive control
slide and the average value of all negative control slides is stored as a noise mitigation constant
to be subtracted from all future images. The aligned CD138 image is turned into a mask of zeros
and ones, so that only myeloma-containing areas have numerical value. The FN and β1 8-bit
images are overlaid and multiplied by the CD138 mask to allow for a maximum value of 65,025.
The square root of this data set (maximum value of 255) is the EMDR score. In addition to this
score, algorithms utilizing nearly identical processes are run to create the scores of FN and β1 in
their respective slides, including areas with and without MM (CD138) and the slide as a whole.
A detailed diagram of the EMDR computational process is presented in Figure 2.2.

2.6 Cluster/Aggregation Determination
The clustering of MM cells from patient primary samples is analyzed throughout
patients’ histories to further explore mechanisms of drug resistance. Four replicate images of
control wells from the aforementioned ex vivo assay46 at time point zero, imaged in phase
contrast at 5x magnification, are saved and quantified to determine the number of neighbors that
each live cell has within a 20-pixel diameter. This diameter was chosen with care to ensure a
window that is large enough to capture multiple cells, but not large enough to count cells that are
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un-clustered or far apart. The typical MM patient primary cell is 5-8 pixels in diameter. The
mean number of neighbors for each cell in the well is a straight forward and accurate way to
quantify the phenotypic clustering that can occur in patient samples (such as in case 2). In
supplementation of these results, a cohort of 11 patients were quantified for number of neighbors
and plotted versus the sum of the area under the curves from our ex vivo assay (Silva et al. In
review). A graph is synthesized for each drug in this manner to determine if any linear
correlation exists between therapy resistance and the phenotypic clustering we seek to further
understand.

2.7 Chapter Two Figures
• From MM-FISH Reports, determine what abnormalities are present across
patient biopsies.
• Determine which biopsies must be mutually exclusive based on
Initial Report chromosomal location.

Analysis

• Following the principle of maximum parsimony, expect the most ‘straightline’ path of genetic mutation, realizing that emergence is more likely to be
based on complexity rather than chronology.
Abnormalities • Group the tumor burden by percentage across the biopsies to determine the
most likely mutation paths.
to clones

Phylogenetic
Tree Synthesis

• Label these clones and map the phylogenetic tree that most likely represents
the FISH report in its entirety.
• Note that unknown percentages are not necessarily normal, they are untested
by standard of care FISH probes.

Figure 2.1: Flow of Information: FISH Report Analysis. Flow of information for analysis of
FISH reports and determination of phylogeny of tumor subpopulations for each patient and the
extrapolation of this information to determine clonal dynamics.
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Noise
Mitigation

Alignment

EMDR Score
Calculation

• Prompt to select control images location.
• Use positive CD138 control to determine threshold level of MM detection.
• Determine average background noise value from all negative controls and subtract this value
from all future images.

• Prompt to select the cropped patient slides location.
• Open first two slides and run images to stack and align via Rigid Body transformation
• Run stack to images and add all slides one by one, repeating the transformation until all slides
are properly aligned.

• Transform CD138 aligned slide into a mask, representing MM-present pixels as ones and all
other pixels as zeros.
• Multiply the aligned FN and Beta1 values to this mask, taking the square root of the result. This
is the EMDR score.
• Repeat this process, reversing the mask to represent non-MM pixels and determine the scores
similarly.
• Finally, do not use the mask and ascertain the intensity of the whole slides to FN and Beta1.

Figure 2.2: Flow of Information: EMDR Analysis. Algorithmic procedure for determining
EMDR score for each patient biopsy. This outline is designed to contribute to holistic
understanding of the ImageJ macro, as all steps once run are automatic.
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CHAPTER 3: RESULTS
3.1 Clinical Relapse is Followed by Tumor Population Turnover
Analysis of tumor phylogeny across patient clinical history provides insight into the
development and progression of tumor cell heterogeneity and drug resistance. The case shown in
Figure 3.1 presents a patient treated over nearly 80 months (case 1). The serum free light chain
(SFLC) measurement throughout the course of treatment is presented with therapy regimen in
panel A. Four sequential relapse events occur between bone marrow biopsy (BMBx) 1 and 7,
with a sharp relapse spike in SFLC from BMBx 7 to 8 that remains relatively consistent through
the remaining two biopsies (9 and 10). MM-FISH reports from these biopsies may be analyzed
and interpreted to generate clonal dynamic and phylogenetic tree representations.
This patient has a fairly complex phylogenetic tree (Figure 3.1C). Starting from clones 1
through 3, subsequent clones contain the same abnormalities as their predecessors with
additional mutations, creating more complex tumor subpopulations. For example, from clone 1.1
to 1.2, an additional translocation of 11q and 14q presents itself, and from clone 3.2 to 3.2.1, a
deletion of the 14q chromosome appears. Clonal dynamics seen in Figure 3.1B appear minimal
until bone marrow biopsy (BMBx) 8, which is matched by a sharp spike in tumor burden (Figure
3.1A). From this point onward, more complex clones tend to take the place of their ‘parent’
clones. This behavior can also be seen in cases 3 and 4 (Supplemental Figures A.5 and A.7
respectively).
Case 3 has a steadily increasing tumor burden that is accompanied by clonal dynamic
shifts. We see from Figure A.5F that the phylogeny is one straight line, and Figure A.5D shows
10

that from BMBx1 to 3, clone 1.1 is steadily overtaking clone 1, and clone 1.1.1 emerges rapidly
between biopsies 2 and 3. Case 4 shows similar results (Figure A.7D). From BMBx1 to 2, clone
1 is overtaken by daughter clones 1.1 and 1.2. From BMBx 2 to 3, clone 1.1 remains present
while clone 1.2.1 begins to overtake its parent clone (clone 1.2). Case 7 represents a
straightforward phylogeny with only one clone containing one abnormality (Supplemental Figure
A.11). From BMBx 2 to 4 in this case, while undergoing no treatment, the tumor appears to
relapse slowly with a concurrent growth rate of clone 1, suggesting that these cells have some
sort of survival advantage over the non-mutated remainder. Case 5 presents an interesting
phenomenon of reemergence of a previously undetected parent clone (Supplemental Figure A.8).
In fact, clone 1 is not detected until BMBx4, while daughter clones portray expected behavior in
the first two biopsies. This is also seen in Figure 3.1 with respect to Clone 1.

3.2 Chemotherapeutic Intervention Can Lead to Cross-Resistance for Subsequent Therapy
From panels A, C, and E of Figure 3.2 we see that between biopsies 8 and 10, despite the
lack of a significant tumor burden change, the predicted tumor burden decrease is significantly
higher for Bortezomib, Melphalan, and CRM1i. This cross-resistance occurs while the patient is
treated with TH-302, Bortezomib, and Dexamethasone. From panels B, D, and F, we see there is
treatment between biopsies 3 and 5 of TH-302, Bortezomib, and Dexamethasone as well,
however there is an increase only in Melphalan resistance. This suggests that treatment given
does not result in similar resistance changes for different patients. However, it is important to
note that in all cases encountered during which resistance evolves, there is a marked increase in
resistance to drugs that patients have not been exposed to, suggesting that resistance occurs by
mechanisms that are not unique to one or even a few particular drugs.

11

3.3 Environmental Protection Changes with Tumor Burden and Cell Location
Analysis of EMDR can provide insight into the extent and progression of environmental
protection MM cells are receiving throughout patient therapy. References to FN score and β1
score refer to the CD138-positive regions (blue lines). Figure 3.3 represents a case (case 2) for
which patient response was tracked over nearly 40 months with tumor burden measured using
sM-spike (Figure 3.3A). We see a steady increase in disease progression from BMBx1 to 3 with
a sharper increase from BMBx 3 to 4, leveling out by BMBx 5. It is observed that EMDR score
(Figure 3.3B) increases from BMBx1 to 2, and decreases from BMBx2 onward. FN and β1
scores share the same behavior (Figure 3.3B and 3.3C respectively), though FN score decreases
to a greater extent, falling below even the healthy tissue expression levels. This trend of EMDR
score increase during lower tumor burden levels and EMDR decrease during spikes in tumor
burden is also present in Supplemental Figure A.1 (case 1), where EMDR is consistently
increasing until BMBx 8 at which point there is a dramatic raise in SFLC level. For the
remaining two biopsies, EMDR score decreases. Cases 3, 4, and 5 show no significant change in
EMDR score across sequential biopsies (Supplemental Figures A.5, A.7, and A.8).

3.4 Alternative Mechanisms of Resistance: Clustering
After analysis of clonal dynamics and EMDR for several cases, we noticed that when
compared to our ex vivo results, the variability in cross resistance and sensitivity to drugs varied
between cases 1 and 2, despite being on the same course of treatment (TH302/BTZ/DEX). We
expect, therefore, that there is another mechanism of drug resistance left to explore. In further
analysis of the ex vivo results, we took a look at the images utilized in patient response
prediction and observed an increase in clustering of MM patient cells in case 2, but not in case 1.
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Based on this finding, we developed a novel ‘number of neighbors’ algorithm to quantify the
phenotypic change of patient cell locations and clustering once seeded in the 384-well plate.
Cases 1 and 2 are represented in Figure 3.4A-D. Case 1 (Figure 3.4A and C), from BMBx 8-10
had previously shown a dramatic spike in tumor burden, and stays relatively constant during this
time. The FISH clones appear very complex and show complete population progression of
subpopulations with more chromosomal abnormalities. The ex vivo results for case 1 show
dramatic increase in resistance to both Melphalan and Bortezomib from BMBx 8 to BMBx 10
(Figure 3.2C and E). EMDR begins decreasing over this time period as well (Supplemental
Figure A.1). Clustering of MM primary cells during this time frame, however, appear stagnant
and minimal. The same is observed in case 3, however the tumor burden in this case is
continuously increasing from BMBx 1 to 4 (Supplemental Figure A.5A and A.6), with less
dramatic but still significant change in FISH dynamics as clone 1.1 overcomes clone 1 and clone
1.1.1 emerges as the most fit genetic variation. In case 3, EMDR remains constant across all
biopsies (Figure A.5) and according to ex vivo results (Figure A.6), there is an increased
sensitivity to Melphalan and a steady increase in resistance to Carfilzomib.
In contrast to cases 1 and 3, cases 2 and 6 (Figures A.4 and A.10 respectively) show
significant increase in clustering across sequential biopsies. While FISH, ex vivo, and EMDR
results are unavailable for case 6, we see a response to drug, followed by relapse between
biopsies one and two, which is accompanied by an increase in MM-MM cell adhesion. For case
2, we see an increase in tumor burden, decrease in EMDR, and increase in Melphalan resistance
between BMBx3 and 5. FISH progresses with the emergence and successful growth of clone
1.1.2 and clustering appears to gradually increase across this time window.
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Utilizing the ‘number of neighbors’ algorithm to quantify clustering phenotype across 11
different patients exposed to 25 PKI’s in the 384-well plate ex vivo study (Silva et al In Review)
allowed correlations to be determined between cell survival in the experiment (AUC %) and the
mean number of neighbors for that well (Figure 3.4). A statistically significant non-zero slope
shows such a correlation, which was present in two drugs in the panel, Melphalan and Linifanib.
Significance of these findings suggests a phenotypic clustering mechanism of survival in
response to these two chemotherapeutic agents. The remaining drugs showed a slope that did not
significantly differ from zero, signifying that, although mechanisms of drug resistance may exist
for these agents, MM-MM adhesion displays no indication of being one such mechanism.
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3.5 Chapter Three Figures

Figure 3.1: Case 1 Patient History, Phylogenetic Tree, and Clonal Dynamics. A) Clinical
Patient History based on Serum Free Light Chain measurements over a period of time in months.
Biopsies are labeled and noted by red circles, with plot colors corresponding to the therapeutic
regimen shown in the key. B) Clonal dynamics developed using FISH reports across sequential
biopsies. After abnormalities in each biopsy are analyzed and clonal results discovered, they are
plotted as a column plot representing the appropriate percentage of tumor cells that make up each
genetically mutated subpopulation. C) A phylogenetic tree is synthesized to further describe the
clones present in panel B. These clones are listed with the abnormalities displayed beneath and
are constructed based on the principle of maximum parsimony, understanding that increases in
heterogeneity and complexity occur chronologically, while varying percentages given in FISH
reports represent abnormalities present that may not be mutually exclusive between clonal
subpopulations. We see here that as tumor burden increases toward biopsies eight through ten,
the genetic abnormalities become increasingly complex and represent a larger population of the
tumor burden. (Case 1)
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Figure 3.2: Case 1 and 2 Clinical History and Response Predictions. A-B) Patient clinical
history with tumor burden determined via SFLC. Biopsies are denoted by open circles and
colored lines correspond to therapeutic agents shown in the legend. C-F) Ex vivo
chemosensitivity determined across patient biopsies for several drugs with known
pharmacokinetics. Panels C and D show the LD50 of each drug across treatment and panels E
and F represent the minimum tumor burden expected within 90 days after computational
modeling of patient response. Panels A, C, and E represent case 1 and panels B, D, and F
represent case 2.
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A.

(4)

(5)

(3)
(1)

(2)

C.

B.

D.

Figure 3.3: Case 2 Patient History, EMDR, FN, and Beta1 Scores. A) Patient clinical history
based on M-spike measurements over a period of time in months. Biopsies are labeled and noted
by red circles, with plot colors corresponding to the therapeutic regimen shown in the key. B)
EMDR score based on a maximum value of 255 across patient biopsies. C) FN is scored
independently in the CD138 positive and negative areas as well as the IHC slide as a whole. D)
Integrin β1 scores are determined in the same manner as FN. All scores are normalized by
CD138 negative region intensity. (Case 2)
17

Figure 3.4: Case 1 and Case 2 Homologous MM-MM Adhesion and Clustering Analysis of
Therapeutic Agents. A, B) Clustering, as determined by a ‘number of neighbors’ algorithm, is
plotted with each dot representing a cell in the control well at time zero of the 384-well plate
assay with mean and standard error as black line(s). C, D) Images of 384 well plate after patient
cell seeding. Table) A cohort of 11 patients exposed to 25 PKI’s was analyzed using the
clustering analysis algorithm. A linear trend between resultant cell death in the 384 well plate ex
vivo assay was compared to the mean number of neighbors seen at time zero in the control wells.
P-values, R squared correlation coefficient, and Pearson r values are reported for each drug, with
the two significantly non-zero sloped drugs, Melphalan and Linifanib, plotted (E). X’s and
squares represent two patients that underwent two sequential biopsies, both of which are plotted
for both drugs, resulting in 13 final data points.
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CHAPTER 4: DISCUSSION
4.1 Complex Genetic Mutation and Clonal Evolution as a Mechanism of Relapse and
Cross-Resistance
Analyses in this chapter discuss the results of our work with respect to the different
patient cases. Complete figures with all obtained data for these cases are present in the
Supplemental Figures section of the Appendix. The specifics of high-risk genetic abnormalities
as they pertain to drug resistance and therapy failure in MM have been well-explored47.
However, the origins of these mutations in response to therapy, environmental factors, the effect
of abnormality combinations, and the successful risk stratification based on these abnormalities
remain particularly elusive in MM13. We see from the results of our phylogenetic trees and clonal
dynamic determinations that although these mutations do in fact cause increased risk of relapse,
the results are rarely equivalent regarding depth and duration of response (or lack thereof) and
the development of cross-resistance to therapy. For example, in our cases 1 and 2, the patients
were on the same therapeutic regimen of TH302, BTZ, DEX, both showed marginal response to
the drug (BMBx8-10 in case 1 and BMBx4 to 5 in case 2), and both had over 90% presence of
genetically abnormal clones. However, we see very little change in clonal dynamics for case 2
and a complete clonal extinction event in case 1 where all clones present in BMBx10 are
‘daughter’ clones of those present in BMBx8 with no trace of the ‘parent’ clones remaining.
Also, in both of these time periods, ex vivo clinical predictions show varying cross-resistant
tumors resulting from the therapy. Case 1 shows substantial increase in resistance to Bortezomib
for which he/she was treated, but also a cross-resistance to Melphalan and CRM1i. In contrast,
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case 2 showed development of cross-resistance to Melphalan, but an increased sensitivity to
Bortezomib. Therefore, clinical therapeutic intervention decisions should not be based solely on
genetic abnormality. Likewise, clonal dynamics is only one piece of the puzzle regarding drug
resistance in MM.
Another point worth discussing is the observable evolutionary drive toward heterogeneity
among tumor subpopulations instead of a bottleneck effect similar to BCR-ABL in chronic
myeloid leukemia (CML)48. These speciation events most likely occur to improve the chance for
survival of one of the clonal populations in the face of varying, dynamic therapeutic regimen.
We can see from our results that once speciation leads to a superior clone in the face of a
particular therapy, this clone grows very rapidly and overtakes other less fit clones as in case 2
with clone 1.1.2 between BMBx2 and 4, and case 5 with clone 1.1.1.1 between BMBx1 and 2.

4.2 Exploring the Inverse Trend Between Tumor Burden and EMDR
Human MM cells, when adherent to bone marrow stromal cells, increase IL-6 secretion49.
IL-6 receptors in turn promote production of Janus kinase (Jak)/STAT3, which is known to
increase survival of patient cells under therapeutic conditions29,50-53. Shain et al. demonstrated
that when FN binds to the Integrin α4/β1 dimer on the MM cell surface, the STAT-3 pathway is
further stimulated by increased IL-6 production as a result of preloading gp130. These concepts
are further articulated by our findings regarding the EMDR score. In cases 1 and 2, as treatment
progresses, EMDR score begins to rise. However, both cases also show that once tumor burden
increases dramatically during relapse, the EMDR scores decrease.
We propose that this decrease is due to two primary factors. First, that ligation of integrin
β1 on hematopoietic tumor cells can lead to arrest of the cell cycle54-58. And second, that there is
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limited space in the perivascular niche of the BM, and as tumor burden increases to a size that is
unsustainable within this area, cells must venture to less ideal locations with fewer stromal cells
to promote IL-6 secretion. This also justifies why FN scores decrease at a more rapid rate than
integrin β1 scores, since relocation of tumor cells away from stroma would have a more
immediate effect on FN presence but a delayed decrease in integrin β1 levels in the MM cells.
The rapid proliferation of tumor cells that causes this decrease in factors measured by EMDR
score may be due in part to genetic evolution of more fit subpopulations as well as MM-MM cell
interactions and clustering that create another mechanism of protection to certain treatments such
as Melphalan and Linifanib, as mentioned in our results. In these cases, the surviving cells that
do not contribute to EMDR score would grow faster and render the STAT3 pathway irrelevant to
successful proliferation.

4.3 Possible Advantages of MM-MM Cell Adhesion to Drug Resistance
From clustering results across sequential patient biopsies, we see clearly the presence of
MM cell clustering in two cases, while two others show no evidence of this phenotype at all. We
propose that as EMDR score goes down and cells are forced to move to other areas of the bone
marrow, clustering is one mechanism that promotes survival in the presence of chemotherapeutic
agents. This is supported by a concurrent ‘desire’ for cells to become more genetically complex
and improve resistance through this pathway. From the substantial correlation between high-risk
genetic mutation and N-cadherin overexpression, the homologous adhesion of MM cells may
contribute positively to genetic resistance as well41,43. This may help explain why in patients
such as our Case 1, in which successfully developed complex genetic clones show an increased
ability to survive therapy, the clustering phenotype has been circumvented, while in other cases
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such as Case 2, MM-MM cell adhesion is a necessary step in survival when leaving the
perivascular niche.
Clustering results across 13 samples (from 11 patients) showed correlation between MMMM cell adherence and survival ex vivo while treated with Melphalan or Linifanib. Mechanisms
of resistance to Melphalan in MM primary cells has been previously explored and significant
findings relate cytogenetics, and adhesion to bone marrow stromal cells and FN to increased
tumor survival while exposed to the drug59,60. MM-MM homologous interaction can further this
drug resistance by means of cell cycle inhibition to allow improved DNA repair caused by
alkylating agents43,61. As an ATP-competitive tyrosine kinase inhibitor, Linifanib is effective
against active FMS-like receptor tyrosine kinase 3 (FLT3), other platelet derived growth factor
receptors, and vascular endothelial growth factor receptors62. In vitro, Linifanib has caused
inhibition of several downstream pathways of FLT3, including the Jak/STAT pathway and cell
cycle regulators like Cyclin D and p27k63,64. However, no previous findings have been made
relating MM cell aggregation to Linifanib drug resistance.

4.4 Summary of Findings
A summary of our findings is represented in Figure 4.1. This figure shows a
representation of our proposed schematic of drug resistance evolution. The evolution of drug
resistance begins in the microenvironment where MM cells receive the most protection from
drug due to surrounding stromal cells and serum. As therapy is forced into the environment, cells
begin mutating in a manner representative of natural selection. As mutations fail to protect cells
outside of the perivascular niche, they are destroyed by therapeutic agents. However, once a path
to successful resistance occurs through homologous MM-MM interaction or chromosomal
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mutation, the cells being to survive irrespectively of niche location, causing EMDR score to drop
as clustering occurs or highly complex, ‘best fit’, mutations occur within the cell. Another
important finding suggests that development of resistance to a single agent is rarely the case. In
fact, based on our results it is rare for cross-resistance not to occur, even to drugs that the patient
has never been exposed to. This suggests that the evolution of drug resistance promotes such
resistance in general, not necessarily to a predictable set of drugs. To make matters more
complicated, each patient exhibits drug resistance evolution to different degrees through different
mechanisms that result in different cross-resistances through time. It seems critical that precision
medicine take hold to promote individualized therapy decisions for each patient afflicted with
MM, bearing in mind that each line of therapy may promote resistance to others, even if they
have remained foreign to the patient before that time.
These findings suggest that a change in perspective regarding therapy decision may be
necessary to optimize patient response and limit relapse. Perhaps treatment at high concentration
that more quickly removes the non-resistant cells will simply provide a more conducive
environment for those MM cells that have established improved resistance phenotypes to grow
more quickly. It may be more beneficial, therefore, to limit the number of drugs utilized over
time and present them in concentrations that will manage the growth of sensitive cells and inhibit
more evolutionarily fit subpopulations from taking over the tumoral space. Such therapy
interventions may lead to less dramatic tumor burden reductions initially, but may also prevent
the rapid and nearly inevitable relapse that occurs in MM patients today.
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4.5 Chapter Four Figures

R
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Figure 4.1: The Whole Picture: A Summary of Findings. Circles outlined in solid blue
represent living MM, while the dashed line and gray inside represent those that have succumbed
to therapy (yellow lightning bolt). Black lines on the left represent stromal cells in the
perivascular niche and black ‘fork’ shapes between MM represent the signaling factors that
promote MM-MM adhesion resistance. The blue cell represents successful genetic mutation that
allows survival and drug resistance regardless of location, showing that the ‘best’ fit for
evolutionary survival has been achieved and suggests that relapse will occur.
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APPENDIX A: SUPPLEMENTAL FIGURES
Below are figures comprising all data collected for the seven patient cases analyzed in
this manuscript. N/A signifies that the data was unavailable for collection, not excluded for
ulterior means.
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Figure A.1: Case 1 Patient History, Ex Vivo Results, FISH, and EMDR.
31

Figure A.2: Case 1 Clustering Analysis Results.

32

Figure A.3: Case 2 Patient History, Ex Vivo Results, FISH, and EMDR.
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Figure A.4: Case 2 Clustering Analysis Results.
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Figure A.5: Case 3 Patient History, Ex Vivo Results, FISH, and EMDR.
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Figure A.6: Case 3 Clustering Analysis Results.
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Figure A.7: Case 4 Patient History, FISH, and EMDR.
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Figure A.8: Case 5 Patient History, FISH, and EMDR.
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Figure A.9: Case 6 Patient History.

Figure A.10: Case 6 Clustering Analysis Results.
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Figure A.11: Case 7 Patient History and FISH.
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